Quironsalud Madrid
| Turchia | Austria | Spagna | |
| Chemioterapia per il cancro al fegato | da $1,800 | - | da $570 |
Il Dott. Jaume Capdevila è un medico altamente qualificato, specializzato nel trattamento dei tumori del tratto digerente e del pancreas. Ha conseguito la laurea in medicina e chirurgia presso l'Università di Lleida e si è specializzato in oncologia medica presso l'Ospedale de la Santa Creu i Sant Pau. È membro di diverse organizzazioni professionali, tra cui EORTC, ESMO, ENETS, ASCO, GEMCAD, TTD e GETHI.
Il medico è un oncologo pediatrico con 37 anni di esperienza, specializzato nel trattamento dei disturbi del sangue e nell'esecuzione di procedure come i trapianti di midollo osseo e la terapia ablativa. Attualmente, il medico è Capo dell'Emato-Oncologia Pediatrica presso l'Ospedale Universitario Quironsalud Madrid.<\/p>
Con un prolifico curriculum accademico, il medico ha curato 14 libri, contribuito a 75 capitoli di libri e presentato a oltre 200 conferenze. Il medico è membro di diverse associazioni professionali, tra cui l'Associazione Spagnola di Ematologia Pediatrica e l'Associazione Spagnola di Oncologia Pediatrica.<\/p>
Il medico tratta un'ampia gamma di condizioni, tra cui leucemia, linfoma, mieloma multiplo e vari disturbi ematologici e autoimmuni.<\/p>
Il medico è un oncologo esperto riconosciuto per i trattamenti di successo del cancro al seno. Ha conseguito un MBBS presso l'Università Autónoma de Barcelona e ha completato la sua residenza presso la Clinica Vall d'Hebron. Ha condotto ricerche significative sulla telomerasi a New York.<\/p>
È il capo del programma sul cancro al seno presso HM Delfos e guida i servizi di Oncologia presso Clin del Mar in Spagna. Come direttore del programma di ricerca sul cancro a Del Mar, è un membro di spicco di GEICAM, CIBERONC, AIECA e SEOM. Il medico ha pubblicato 120 articoli su riviste rinomate, accumulando oltre 9000 citazioni.<\/p>
Immunotherapy combination therapy is the primary first-line treatment for advanced liver cancer in Spain. Following Spanish Society of Medical Oncology guidelines, doctors prioritize Atezolizumab plus Bevacizumab over traditional chemotherapy. This approach targets PD-L1 and VEGF proteins to stop tumor growth in hepatocellular carcinoma patients.
Bookimed Expert Insight: Spain ranks third globally for medical requests in our network, partly due to high-volume centers like Clinica Universidad de Navarra. This clinic serves 140,000 patients annually and holds European Society for Medical Oncology accreditation. The sheer volume of operations, reaching 23,500 per year at some Barcelona facilities, ensures surgeons maintain elite proficiency in complex liver cases.
Patient Consensus: Patients value the shift toward immunotherapy because it offers better outcomes than older chemotherapy drugs like Doxorubicin. Many travelers focus their search on Barcelona or Madrid to access specialized multidisciplinary teams and experimental studies.
Spanish oncology centers treat cholangiocarcinoma using Gemcitabine and Cisplatin as the gold-standard first-line therapy. Clinics like Centro Médico Teknon also utilize targeted therapies like futibatinib for specific genetic mutations and immunotherapy agents such as Pembrolizumab to improve patient outcomes in advanced cases.
Bookimed Expert Insight: While basic chemotherapy is standard, Spain’s top-tier centers like Quironsalud Madrid offer unique access to oncology clinical trials. Since Bookimed data shows Spain ranks 3rd globally in our network, patients often benefit from advanced molecular medicine labs in Barcelona that tailor drug combinations based on precise tumor genetics.
Patient Consensus: Patients emphasize the importance of biomarker testing before starting Gem/Cis cycles. Many find that adjusting cisplatin dosages helps manage fatigue while maintaining treatment efficacy.
Chemoembolization is a minimally invasive procedure combining localized chemotherapy with arterial blockage to treat liver cancer. It delivers high-dose drugs directly to tumors through a catheter, sparing healthy tissue. This standard palliative treatment is common for primary and metastatic liver malignancies.
Bookimed Expert Insight: Spain ranks 3 globally for oncology requests, with centers like Clinica Universidad de Navarra leading in JCI-accredited care. While basic chemotherapy in Spain starts at $2,500, choosing centers with multidisciplinary tumor boards is vital. These boards often stage treatments over 12-24 months for extensive liver involvement.
Patient Consensus: Patients value how this procedure acts as a one-two punch against tumors larger than 9 cm. Many appreciate the shorter hospital stay compared to major surgery despite experiencing temporary flu-like symptoms.
Chemotherapy for liver cancer typically lasts between 3 and 12 months, though duration varies by case. Treatment occurs in cycles lasting 2 to 3 weeks, combining infusion days with rest periods. Most regimens include up to 8 cycles to achieve curative or palliative goals.
Bookimed Expert Insight: Spanish oncology centers like Centro Médico Teknon or Clinica Universidad de Navarra often pivot treatment duration based on real-time drug efficacy. Data shows these JCI-accredited facilities focus on 10,000+ patients annually, frequently transitioning long-term patients to clinical trials if standard 6-month cycles reach a plateau.
Patient Consensus: Treatment length depends heavily on whether the cancer started in the liver or spread from elsewhere. Patients emphasize confirming the specific protocol early to plan for potential maintenance therapy lasting over one year.
Spain offers specialized liver cancer chemotherapy at internationally accredited oncology centers in Barcelona and Madrid. Patients access advanced drug protocols alongside targeted therapies and clinical trials. JCI-accredited facilities like Centro Médico Teknon and Clinica Universidad de Navarra lead in integrating chemotherapy with surgical resection for metastatic cases.
Bookimed Expert Insight: While chemotherapy is the standard request, Bookimed data shows Spain is a hub for high-tech alternatives. Clinica Universidad de Navarra serves 140,000 patients annually and is recognized by ESMO for its oncology excellence. If systemic chemotherapy isn't the best fit, these top-tier clinics often pivot to advanced radiotherapies like tomotherapy or CyberKnife, which are widely available across the GenesisCare network.
Patient Consensus: Patients often emphasize that surgery remains the primary goal for potential curability in liver cases. Many advise checking eligibility for Phase 2 clinical trials involving new molecular inhibitors early in the treatment planning process.